ADVANCING THE POWER OF DIAGNOSTIC KNOWLEDGE

What We Do

Alveo is leading the transformation of the consumer health tech market by developing a low-cost, easy- to-use, at-home diagnostic platform that has the potential to change the way infectious diseases are detected and managed. The company’s be.well™** testing system is designed to give individuals access to cutting-edge molecular testing and cloud-based data analytics for rapid diagnosis and management of infectious diseases. With an initial focus on acute respiratory infections including COVID-19, Flu A/B and RSV, Alveo’s agile and dynamic diagnostic platform could be adapted to detect a wide range of diseases that threaten public health. We believe affordable access to real-time, at-home results will transform the way individuals, healthcare providers and public health professionals identify and manage disease outbreaks. With be.well™, we will Know Sooner, Act Faster™ and make better-informed decisions regarding personalized intervention options that benefit individuals and the entire population*..

Who We Are

We are scientists, innovators, data-geeks, and passionate entrepreneurs. We believe that every problem has a clear solution — when you apply the right knowledge and passion. We know that protecting the health of an interconnected global society has never been more crucial. We’re up to the challenge.

We are proud to be Alveo. Meet the team that is changing the world of diagnostics.

Leadership

RON CHIARELLO, PhD

Ron is the Founder, Chief Executive Officer, and Chairman of the Board of Alveo Technologies. Dr. Chiarello is a compassionate and successful business leader who has led a distinguished career building on more than 25 years of expertise in designing, developing and manufacturing cutting-edge micro-fluidic, micro-electronics and semiconductor technologies. An entrepreneur at heart, Dr. Chiarello has successfully founded, led, and sold multiple startups specializing in applying these technologies to a range of sensing and diagnostic challenges.

Alveo Technologies was born out of Dr. Chiarello’s vision to transform the way the medical field diagnoses, tracks, and treats infectious disease. The company’s novel diagnostic platform, be.well, has been in development since 2015. With this technology, real-time, low-cost disease detection will become broadly accessible, and could revolutionize the way we respond to, and recover from, the threat of infectious diseases like flu, RSV, COVI-19, and new threats yet to be discovered.

Prior to Alveo, Dr. Chiarello co-founded Jetalon Solutions in 2002, where he led the development and commercial deployment of Jetalon’s sensor solutions to micro-electronic, biopharmaceutical, petrochemical, and solar cell manufacturers world-wide. In 2009, Dr. Chiarello was appointed CEO of Jetalon, a position he held until 2013 when the company was acquired by Entegris. He also founded and sold Etalon Technologies (1997-2002) and Orion Metrology (2007-2010), and has provided technical advising services to many high-profile technology companies and government agencies on subjects like product development, manufacturing improvements, and environmental concerns.

Dr. Chiarello earned his Bachelor of Science in Physics at the University of California Santa Barbara and his Doctor of Philosophy (Ph.D.) in Physics from Northeastern University. Dr. Chiarello has spent more than a decade in research and development working with institutions like Argonne National Laboratory, the University of Chicago, and Stanford University, where he functioned as a program director for a number of years. Dr. Chiarello has published more than 50 technical articles, is a NATO fellow, and was the recipient of the Department of Energy Award for Excellence in Research, and the University of Chicago’s Pace Setter Award.

MIKE AICHER, MBA
Mike is the President and a Founder of Alveo Technologies. Prior to Alveo, Mike co-founded and served as National Genetics Institute’s (NGI) CEO from 1991 to 2012. NGI became a wholly-owned subsidiary of Laboratory Corporation of America (NASDAQ: LH) in 2000, where he held various positions. He ran the company’s “Esoteric Business Units”, which generated over $1 billion in annual revenue.

Mike holds a Bachelor of Science in Business Administration from the University of Redlands, a Master of Business Administration in Economics from Columbus University and is a certified Global Biotechnology Executive from the University of California, Berkeley. He has also received Ernst and Young’s “Entrepreneur of the Year” award for emerging technologies.

ROBIN STEELE, JD, LL M
Robin is a member of the Alveo Board of Directors and has practiced corporate and tax law for 30 years, primarily in the biotechnology and pharmaceutical industries. She has extensive experience in financings, collaborations and M&A. Most recently Robin served 10 years as Senior Vice President and General Counsel to InterMune, Inc., a publicly traded (NASDAQ) biopharmaceutical company that was acquired by Roche in late 2014.

Robin previously served eight years as Vice President of Legal Affairs for Elan Pharmaceuticals, a publicly-traded (NYSE) global pharmaceutical company headquartered in Dublin, Ireland.

Robin received a bachelor’s degree in biology from the University of Colorado, a J.D. degree from the University of California, Hastings College of the Law, and a LL.M. in Taxation from New York University School of Law.

BHARAT TEWARIE, MD, MBA
Dr. Bharat Tewarie is a C-suite leader with deep expertise in developing, shaping, and turning around biopharma companies to outpace competitors and achieve #1 performance. He gained an extensive background in multiple aspects of pharmaceutical management, including P&L responsibility, corporate strategy, marketing, access, insights, sales, product launches and business development.
He gathered a compelling track record in structuring commercial organizations across settings, cultures, and geographies (USA and Europe) for profitable product performance and has been a catalyst for change and transformation in both global and local roles at Boehringer Ingelheim, Roche, Serono International, EMD Serono and Merck Serono.
After working for the last five years as the EVP & Chief Marketing Officer and member of the Executive Committee of UCB, he founded in 2020 the advisory firm Boston BioPharma Consultants and became a member of the Board of Advisors of Ahara Biosciences and Duluth Medical Technologies.
He is a thought leader on the topics of Patient Value, Product and Medical Device Launches, Patient Experience, Digital Technologies and specifically AI to address biopharma business challenges.
He joined Alveo Technologies in March 2020 as a member of the Board of Directors.
JULIANNE AVERILL

Julianne Averill is the Chief Financial Officer at Alveo Technologies.  Prior to Alveo, Julianne was VP, Finance at BlackThorn Therapeutics and she has also spent 18+ years in various leadership positions helping organizations in the life sciences and digital health fields scale their finance, accounting, and business operations. She has participated in or led over $2B in successful strategic financing and M&A initiatives accretive to growth.

Julianne is licensed as an active Certified Public Accountant in the State of California and is also a Society of Human Resource Management Certified Professional. She graduated with Distinction from California State University, Fresno, with a Master’s of Accountancy and Summa Cum Laude with a Bachelor’s of Science in Business Administration.

JOHNSON CHIANG, PhD
Previous to Alveo Technologies, Johnson was the Head of Systems Integration & Molecular Biology at Foundation Medicine, Inc. and held senior management positions at Life Technologies and Thermo Fisher Scientific where he led systems design, integration, verification and validation for qPCR and next-generation sequencing platforms.

Johnson has led a number of molecular diagnostic product development projects from concept to commercialization at Applied MEMS, Applied Biosystems Inc., and Cepheid; designed and developed several successful microfluidics products; filed several patents; and published numerous biotechnology papers. He has extensive experience in instrument development as well as design control for 510k and PMA applications.

JOHN TOMPKINS, MSc, MBA

John is the Executive Vice President of Engineering and Operations. John comes to this position from Siemens Healthineers Molecular Diagnostics where he led Program Management, PMO and New Product Introduction. Before that he was responsible for leading consulting organizations in the product development, product management, strategy and supply-chain space drawing on his previous experience in product development and supply-chain in several industries including in-vitro diagnostics and high-volume tech products.

John holds a Bachelors Degree in Mechanical Engineering from Kingston University (UK), a Masters Degree in Engineering Design from Loughborough University (UK) and an MBA from Henley Management College (UK). He is also a Professional Engineer (Oregon), Chartered Engineer (UK) and a Member of the Institution of Mechanical Engineers (UK).

BRENNA LORD
Brenna is Vice President at Alveo Technologies. She balances diverse responsibilities for the company, including IP, HR, recruiting, quality, regulatory, facilities, event coordination, contracts, and communications.

Prior to Alveo, Brenna held a variety of technical and leadership roles at Guidant Corporation/Abbott Vascular from 2004 to 2014, including: Group Lead of the design team for R&D implant projects; Principal/Staff Engineer focused on scaffold design and transfer to manufacturing for the first drug-eluting bioresorbable vascular scaffold to treat coronary artery disease; and Co-Chair of the Abbott Vascular Technology Exposition (2011-2012).

Brenna has successfully supported and led the development of multiple medical device products from early concept stage through design control, verification and validation, and regulatory submission. She holds 10+ patents and received the Abbott Vascular R&D Excellence Award in 2006, 2009, and 2010. Brenna earned her Bachelor of Science and Master of Science degrees from Stanford University in Mechanical Engineering.

KYLE MONTGOMERY
Kyle is the Engineering Director at Alveo Technologies, guiding products from early-stage R&D to manufacturing. At Alveo, Kyle has held roles of increasing responsibility including New Product Development Engineer and Engineering Manager.

Prior to his time with Alveo, Kyle worked at Entegris Jetalon as a New Product Development Engineer, serving as the team lead and taking multiple semiconductor sensor products from concept to market. Kyle received his Bachelor of Science degree from Arizona State University in Earth and Space Exploration.

MITCHELL AICHER
Mitchell is Vice President of Product at Alveo Technologies. Mitchell is responsible Alveo’s information, people, activities and resources involved in moving the company’s products and services from supplier to customers. Mitchell previously worked at Roche where he supported its international sequencing and sample preparation efforts.

Prior to Roche, Mitchell served as a Director for Kinetic Diagnostics, which utilizes genomic data in an effort to maximize athletic performance and at Laboratory Corporation of America (NASDAQ: LH) where he served in various finance and IT roles. Mitchell holds a Bachelor of Science in Business Administration and Entrepreneurship from Loyola Marymount University.

AMAN ULLAH
Aman is the Director of Manufacturing at Alveo Technologies and is responsible for developing and implementing a sustainable manufacturing strategy for new product introductions. Aman joined Alveo from Siemens Healthineers where he was Head of New Product Introductions for the molecular diagnostics division. At Siemens, Aman was deeply involved with numerous diagnostic development projects from concept through commercialization.

Prior to Siemens, Aman worked at Chrysler LLC where he was responsible for high-volume automation scale-up and manufacturing management across multiple new vehicle launches. Aman earned his Bachelor of Science and Master of Science degrees in Mechanical Engineering from Wayne State University and Oakland University respectively.

KEVIN GUNNING
Kevin is responsible for Alveo’s Quality Management System. He brings with him over 25 years of experience working in the medical device, pharmaceutical, biotechnology, and clinical laboratory industries.

Kevin has successfully developed, implemented, and managed quality systems for a number of organizations, ranging from fledgling startups to established global corporations. He holds a bachelor’s degree in biological sciences from State University of New York at Buffalo and is an ASQ-certified Quality Auditor.

RIXUN FANG, PhD
Rixun brings over 20 years of experience in IVD development to his role as Alveo’s Director of Assay Development. He has successfully led many projects from inception through development and implementation at Applied Biosystems, Life Technologies, and Thermo Fisher Scientific, following GMP/QSR/ISO compliances and the PCP process.

He has worked through IVD product 510k and PMA submissions with FDA, initiated and led collaborative projects with many internationally well-known institutions, holds six patents, and has authored multiple publications.

ROBERT DI TULLIO
Robert Di Tullio is an experienced industry expert providing custom quality and regulatory solutions to the medical devices industry, specializing in diagnostics, as President of Di Tullio Consulting Inc., since 2013. He has 46 years of experience in the In Vitro Diagnostics Industry, the last 35 of which is in regulatory, clinical and quality management. Previously, he was Vice President, Global Regulatory and Clinical Affairs for Alere Inc. from 2010 until 2013, and held similar positions at ProteoGenix, Sequenom, Siemens Medical Solutions Diagnostics and Diagnostic Products Corporation.

Robert was the Co-Chair of the AdvaMed Diagnostics Task Force from 2007 until 2013, the Diagnostics Industry Liaison to the Clinical Laboratory Improvement Advisory Committee (CLIAC) from 2011 until 2014 and is a long-time member of the Regulatory Affairs Professionals Society (RAPS). He was an advisory board member for the medical device graduate degree curriculum at the University of Southern California from 2004 until 2006. Robert received a Bachelor of Science in Biology from Saint Joseph’s University in Philadelphia.

SHAD PIERSON
Shad is the Senior Hardware Engineer / Technology Architect at Alveo Technologies. Shad conceptualizes technical solutions to bring visionary ideas to the benchtop for testing. His contributions range from algorithm development to PCB design and bring-up to new intellectual property generation.

Prior to Alveo, Shad worked at Entegris Jetalon as a Research Engineer, guiding the early stage development of multiple products. Shad has a bachelor’s degree in mathematics from the University of California, Davis.

Scientific Advisory Board Members

PAUL BILLINGS, MD, PhD

Chief Medical Officer, Life Technologies, Inc. acquired by Thermo Fisher (2014)

GEORGE CHURCH, PhD

Professor at Harvard & MIT, Geneticist, molecular engineer, chemist

JOHN DEVINCENZO, MD

Professor at University of Tennessee, Medical Director Le Bonheur Children’s Hospital, pediatric RSV expert

MARCIA EISENBERG, PhD

Chief Scientific Officer, LabCorp

POOJA GOEL

Managing Director of Virgo Investments Group

ROGER HAWLEY

CEO/Co–Founder of Zogenix (ZGNX)

CHARLES MOSHER, MBA

President and CEO of HemaStrat LLC

SUMITA PENNATHUR, PhD 

Professor of Mechanical Engineering, UCSB, Director of Pennathur Laboratory for nanotechnology for bio sensing

KEVIN PLAXCO, PhD

Professor of Biomolecular Science and Mechanical Engineering, and the Associate Director of The Center for Bioengineering at UCSB

JUSTIN STEBBING, MD, PhD

Professor of Cancer Medicine, Editor-in-Chief Oncogene

MYRON TONG, MD, PhD

World–leading Hepatologist, practicing physician at UCLA Medical Center

JAY G WOHLGEMUTH, MD

Chief Medical Officer, Quest Diagnostics

1000 Atlantic Avenue, Suite 114
Alameda, CA 94501

[email protected]
510.749.4895

*The be.well system is currently under development to be used by individuals over the age of 18, and for individuals over the age of 18 to perform the test on individuals under 18 years of age.
** The be.well  system is currently under development and has not received clearance, approval, or any other marketing authorization from the U.S. FDA.

error: Content Restricted